

ATHENA acquires INPHARMASCI France and extend its manufacturing capacity in Europe

Dear Partner,

ATHENA, a French based company with existing Manufacturing and R&D operations in India announces the acquisition of the manufacturing factory INPHARMASCI on 15th January 2020. The acquired factory of 11K sqm² located in Prouvy-France is specialised in Oral Solid Dose manufacturing.

“We see great potential for the manufacturing facility in France. The synergies of Athena existing and pipeline dossiers with INPHARMASCI manufacturing capacity and knowledge will significantly enhance our opportunities to serve our customers in Europe but also in Export markets” quoted Alexandre Williams, Managing director of ATHENA S.A.S.

About INPHARMASCI:

INPHARMASCI is an EU GMP approved facility specialised in Oral Solid Dose manufacturing for Specialty and Generic clients in Europe with a French focus. INPHARMASCI has over 115 staff specialised in dry forms and the manufacturing of uncoated, coated and sugar coated tablets, capsules, pills and stick pack. Our expertise includes special processes and tablet forms including wet granulation, oral dispersible tablet Technology, sustained-release products. In addition to the industrial production operations which represent our core business, INPHARMASCI also offer a wide range of services such as Analysis of statutory files Technical support for product development, Industrial transposition, Process validation, Stability analyses, and Routine analyses.

About ATHENA:

Athena with its EU GMP approved facility and state of art R&D centre is focused on the innovative and value added products in mature and emerging markets and is engaged in Licensing and Development model for Specialty Pharma, Multinationals and other established companies. Athena provides comprehensive product lifecycle management solutions for Oral Solids based on its proprietary technology's platforms. Athena has already developed many innovative products CTD format viz., Esomeprazole 20-40 mg Capsules, Fenofibrate Capsules/Tablets 160-200-267 mg, Ibuprofen 200-400 mg ODT, Levoceterizine 5 mg ODT, Meloxicam 7.5-15 mg ODT, Metformin 750mg,SR Tablets Ondansetron 4-8 mg ODT, Prednisolone 1-5-10 mg Soluble and ODT, Racecadotril 10-30 mg Sachets, Secnidazole High Dose 2 grams Sachet , Tramadol Paracetamol 37.5+325 mg ODT, Zolpidem 5 - 10 mg ODT & SL ODT. These products are already or under registration marketed by leading companies across geographies.

For further information, please contact

Mrs Shradha Patel patel.shradha@ddsathena.com

Mr Ribeaux François francois.ribeaux@inpharmasci.com

visit www.athenadds.com and <https://www.inpharmasci.com/>